Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies

Ole Jakob Storebø, Nadia Pedersen, Erica Ramstad, Maja Lærke Kielsholm, Signe Sofie Nielsen, Helle B. Krogh, Carlos R. Moreira‐Maia, Frederik L. Magnusson, Mathilde Holmskov, Trine Gerner, Maria Skoog, Susanne Rosendal, Camilla Groth, Donna Gillies, Kirsten Buch Rasmussen, Dorothy Gauci, Morris Zwi, Richard Kirubakaran, Sasja J. Håkonsen, Lise AagaardErik Simonsen, Christian Gluud

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non‐serious adverse events.
OriginalsprogEngelsk
ArtikelnummerCD012069
TidsskriftCochrane Database of Systematic Reviews
Udgave nummer5
DOI
StatusUdgivet - 2018

Fingeraftryk

Udforsk hvilke forskningsemner 'Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies' indeholder.

Citationsformater